An Open-label, Multicenter Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in an F.Hoffmann-la Roche- and/or Genentech- Sponsored Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Onartuzumab (Primary) ; Bevacizumab; Erlotinib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical; Roche
- 23 Nov 2017 Planned End Date changed from 22 Aug 2017 to 25 Jan 2018.
- 23 Nov 2017 Planned primary completion date changed from 22 Aug 2017 to 25 Jan 2018.
- 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.